Why the study?
Does continuing dual antiplatelet therapy increase bleeding risk in patients undergoing major surgical or endoscopic procedures?
Does continuing dual antiplatelet therapy increase bleeding risk in patients undergoing major surgical or endoscopic procedures?
Despite current guidelines recommending postponement of surgery after stent placement, this small case series suggests major surgical and endoscopic procedures might be performed safely while continuing dual antiplatelet therapy.
Dual antiplatelet therapy (i.e., aspirin and clopidogrel) is mandatory after acute coronary syndrome or stent implantation because coronary lesions and stents behave like unstable plaques as long as they are not fully covered by a cellular layer. Current guidelines recommend that elective, noncardiac surgery should be postponed for at least 6 weeks after the placement of bare-metal stents and for at least 12 months after the placement of drug-eluting stents. With this question in mind, Abdel Samie et al. 2 reported a small case series of 11 consecutive patients who underwent biliary-pancreatic surgery or endoscopic intervention while receiving dual antiplatelet therapy. In this retrospective study, neither immediate nor clinically significant delayed bleeding was reported in patients with endoscopic sphincterotomy (n=9) and major surgery (n=2). Although this study has only a limited number of patients, its results suggest that even major surgical and endoscopic procedures can be performed safely in patients who continue dual antiplatelet therapy.
No takes yet. Share an insight, caveat, or question.
Young Koog Cheon (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: